COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study

被引：0
|
作者：
Alexander T. Cohen
Anthony Maraveyas
Jan Beyer-Westendorf
Agnes Y. Y. Lee
Lorenzo G. Mantovani
Miriam Bach
机构：
[1] King’s College London,Department of Haematological Medicine, Guys and St Thomas’ NHS Foundation Trust
[2] Castle Hill Hospital,Joint Centre for Cancer Studies, Hull York Medical School, QCOH
[3] University Hospital “Carl Gustav Carus” Dresden,Thrombosis Research Unit, Department of Medicine I, Division Hematology
[4] Kings College London,Kings Thrombosis Service, Department of Haematology
[5] University of British Columbia,Division of Hematology
[6] British Columbia Cancer Agency,CESP
[7] University of Milan Bicocca,Center for Public Health Research
[8] Bayer AG,undefined
来源：
Thrombosis Journal | / 16卷
关键词：
Active cancer; Health-related quality of life; Low molecular weight heparin; Patient preference; Recurrent venous thromboembolism; Rivaroxaban; Vitamin K antagonist;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Predictors of Interventional Treatment Use for Venous Thromboembolism in Cancer Patients
    Yoon, Lara
    Clarke Hillyer, Grace
    Chen, Ling
    Hu, Jim C.
    Neugut, Alfred I.
    Hershman, Dawn L.
    Wright, Jason D.
    CANCER INVESTIGATION, 2016, 34 (08) : 408 - 414
  • [22] Safety and effectiveness of oral rivaroxaban for the treatment of venous thromboembolism in cancer patients
    Kondo, Y.
    Hirabatake, M.
    Satake, H.
    Yasui, H.
    Hashida, T.
    ANNALS OF ONCOLOGY, 2017, 28 : 165 - 165
  • [23] Risk of recurrence and bleeding with Rivaroxaban among patients with venous thromboembolism and active cancer
    Sogaard, M.
    Nielsen, P. B.
    Skjoth, F.
    Kjaeldgaard, J. N.
    Larsen, T. B.
    THROMBOSIS RESEARCH, 2018, 164 : S240 - S240
  • [24] TREATMENT AND SECONDARY PREVENTION OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS
    Shakaryants, G. A.
    Budanova, D. A.
    Lobastov, K., V
    Khabarova, N., V
    Kirichenko, Y. Y.
    Belenkov, Y. N.
    KARDIOLOGIYA, 2020, 60 (03) : 71 - 79
  • [25] New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients
    Gerotziafas, Grigoris T.
    Mahe, Isabelle
    Elalamy, Ismail
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 423 - 436
  • [26] Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
    Alexander T. Cohen
    Cihan Ay
    Philippe Hainaut
    Hervé Décousus
    Ulrich Hoffmann
    Sean Gaine
    Michiel Coppens
    Pedro Marques da Silva
    David Jiménez
    Beatrice Amann-Vesti
    Bernd Brüggenjürgen
    Pierre Levy
    Julio Lopez Bastida
    Eric Vicaut
    Petra Laeis
    Eva-Maria Fronk
    Wolfgang Zierhut
    Thomas Malzer
    Peter Bramlage
    Giancarlo Agnelli
    Thrombosis Journal, 16
  • [27] Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
    Cohen, Alexander T.
    Ay, Cihan
    Hainaut, Philippe
    Decousus, Herve
    Hoffmann, Ulrich
    Gaine, Sean
    Coppens, Michiel
    da Silva, Pedro Marques
    Jimenez Castro, David
    Amann-Vesti, Beatrice
    Brueggenjuergen, Bernd
    Levy, Pierre
    Lopez Bastida, Julio
    Vicaut, Eric
    Laeis, Petra
    Fronk, Eva-Maria
    Zierhut, Wolfgang
    Malzer, Thomas
    Bramlage, Peter
    Agnelli, Giancarlo
    THROMBOSIS JOURNAL, 2018, 16
  • [28] Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience
    Pignataro, Bruno Soriano
    Nishinari, Kenji
    Cavalcante, Rafael Noronha
    Centofanti, Guilherme
    Yazbek, Guilherme
    Krutman, Mariana
    Zotelle Bomfim, Guilherme Andre
    Imagawa Fonseca, Igor Yoshio
    Teivelis, Marcelo Passos
    Wolosker, Nelson
    Sanches, Solange Moraes
    Ramacciotti, Eduardo
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2017, 23 (07) : 883 - 887
  • [29] Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial
    Yhim, Ho-Young
    Choi, Won-Il
    Kim, Sung-Hyun
    Nam, Seung-Hyun
    Kim, Kyoung Ha
    Mun, Yeung-Chul
    Oh, Doyeun
    Hwang, Hun-Gyu
    Lee, Keun-Wook
    Song, Eun-Kee
    Kwon, Yong Shik
    Bang, Soo-Mee
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (05): : 1125 - 1135
  • [30] Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
    Cohen, A. T.
    Maraveyas, A.
    Beyer-Westendorf, J.
    Lee, A. Y. Y.
    Mantovani, L. G.
    Folkerts, K.
    Bach, M.
    De Sanctis, Y.
    Abdelgawad, K.
    ANNALS OF ONCOLOGY, 2019, 30
12345